Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension

Leiter, Lawrence A., Cefalu, William T., de Bruin, Tjerk W. A., Gause‐Nilsson, Ingrid, Sugg, Jennifer, Parikh, Shamik J. · 2014 · Journal of the American Geriatrics Society

Abstract

Objectives: To assess the efficacy of dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, for the treatment of individuals with type 2 diabetes mellitus (T2 DM ) and preexisting cardiovascular disease ( CVD ). Design: Randomized, double‐blind, age‐stratified (<65 and ≥65), 24‐week clinical trial with a 28‐week extension. Setting: One hundred seventy‐three centers in 10 countries. Participants: Individuals (N = 964) with T2 DM , glycosylated hemoglobin (HbA1c) of 7.0% to 10.0%, and documented CVD . Intervention: Dapagliflozin 10 mg/d or placebo was added to usual care. Participants receiving insulin had their total daily insulin dose reduced by 25% at randomization. Measurements: Two equal primary end points: change from baseline in HbA1c and proportion of participants achieving a three‐item end point (reduction of ≥0.5% in HbA1c, ≥3% in body weight, and ≥3 mmHg in systolic blood pressure) at 24 weeks. Results: Forty‐seven percent were aged 65 and older, 7.7% were aged 75 and older, mean duration of T2 DM was 13 years, mean baseline HbA1c was 8.1%, and approximately 60% were taking insulin. The placebo‐corrected change in HbA1c with dapagliflozin was −0.4% at 24 weeks. Significantly more participants achieved the three‐item end point with dapagliflozin (10.0%) than with placebo (1.9%). The placebo‐corrected percentage change in body weight for dapagliflozin was −1.9% (−1.8 kg). Similar results were observed in both age strata, and changes were maintained over 52 weeks. More than one‐quarter (28.2%) of participants receiving dapagliflozin and 25.3% of those receiving placebo experienced hypoglycemia. More participants receiving dapagliflozin had vulvovaginitis, balanitis, or urinary tract infection. Conclusion: When added to a usual background regimen in an older population with advanced T2 DM and preexisting comorbid CVD , dapagliflozin improved glycemic control without an increase in hypoglycemic risk, promoted weight loss, and was well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jgs.12881

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Metadata

Authors
Leiter, L. A., Cefalu, W. T., de Bruin, T. W. A., Gause‐Nilsson, I., Sugg, J., & Parikh, S. J.
Venue
Journal of the American Geriatrics Society
Publisher
Wiley
Published
2014-06-02
Volume
62
Issue
7
Pages
1252-1262
ISSN
  • 0002-8614 (ISSN-L)
  • 1532-5415
OpenAlex
W2054361323
Cited by
182
References
8
FWCI
14.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension. https://app.cochat.ai/papers/10.1111/jgs.12881
The paper
Leiter, L. A., Cefalu, W. T., de Bruin, T. W. A., Gause‐Nilsson, I., Sugg, J., & Parikh, S. J. (2014). Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12881

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.